• Je něco špatně v tomto záznamu ?

Use Via Early Access to Ixazomib (UVEA-IXA) Study: Effectiveness and Safety of Ixazomib-based Therapy in Relapsed/Refractory Multiple Myeloma Outside of the Clinical Trial Setting

H. Ludwig, K. Ramasamy, MV. Mateos, B. Kishore, V. Gergely, M. Ladicka, A. Ori, L. Simoni, N. Bent-Ennakhil, DM. Stull, F. Gavini, E. Terpos, R. Hájek

. 2024 ; 24 (2) : e40-e49.e3. [pub] 20231014

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc24007392

BACKGROUND: In multiple myeloma (MM), improving our understanding of routine clinical practice and the effectiveness of agents outside of clinical trials is important. TOURMALINE-MM1 data resulted in approval of ixazomib for MM patients who have received ≥ 1 prior therapy. PATIENTS AND METHODS: UVEA-IXA comprised a retrospective chart review in the early access program, and a prospective 1-year follow-up period. Eligible patients had had a biochemical and/or symptomatic relapse after 1-3 prior lines of therapy; no anti-MM therapy for > 3 cycles at the start of ixazomib therapy; and an Eastern Cooperative Oncology Group performance score of 0-2. Lenalidomide- or proteasome inhibitor (PI)-refractory patients were ineligible. Primary endpoints were response and progression-free survival (PFS). RESULTS: Of 357 enrolled patients, 309 were evaluable; most patients received ixazomib alongside lenalidomide (98%) and dexamethasone (97%); 61% had received 2-3 prior lines of therapy. Median PFS was 15.6 months (95% confidence interval [CI]: 12.0-20.6) in all evaluable patients, and 19.6 (95% CI: 12.1-27.0) and 13.9 (95% CI: 10.1-18.1) months in patients who received 1 and ≥ 2 prior lines of therapy, respectively. The overall response rate was 67% in all evaluable patients, and 72% and 63%, respectively, in patients who received 1 and ≥ 2 prior lines of therapy. Median overall survival was 35.5 months. The ixazomib safety profile was consistent with previous reports. CONCLUSION: This study supports ixazomib-based therapy as an effective and tolerable treatment in the real-world. Outcomes were favorable in patients with 1 or ≥ 2 prior lines of therapy who were not lenalidomide- or PI-refractory.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24007392
003      
CZ-PrNML
005      
20240423155923.0
007      
ta
008      
240412s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.clml.2023.10.003 $2 doi
035    __
$a (PubMed)37996265
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Ludwig, Heinz $u First Department of Medicine, Wilhelminen Cancer Research Institute, Center for Oncology and Hematology, Clinic Ottakring, Vienna, Austria. Electronic address: heinz.ludwig@extern.gesundheitsverbund.at
245    10
$a Use Via Early Access to Ixazomib (UVEA-IXA) Study: Effectiveness and Safety of Ixazomib-based Therapy in Relapsed/Refractory Multiple Myeloma Outside of the Clinical Trial Setting / $c H. Ludwig, K. Ramasamy, MV. Mateos, B. Kishore, V. Gergely, M. Ladicka, A. Ori, L. Simoni, N. Bent-Ennakhil, DM. Stull, F. Gavini, E. Terpos, R. Hájek
520    9_
$a BACKGROUND: In multiple myeloma (MM), improving our understanding of routine clinical practice and the effectiveness of agents outside of clinical trials is important. TOURMALINE-MM1 data resulted in approval of ixazomib for MM patients who have received ≥ 1 prior therapy. PATIENTS AND METHODS: UVEA-IXA comprised a retrospective chart review in the early access program, and a prospective 1-year follow-up period. Eligible patients had had a biochemical and/or symptomatic relapse after 1-3 prior lines of therapy; no anti-MM therapy for > 3 cycles at the start of ixazomib therapy; and an Eastern Cooperative Oncology Group performance score of 0-2. Lenalidomide- or proteasome inhibitor (PI)-refractory patients were ineligible. Primary endpoints were response and progression-free survival (PFS). RESULTS: Of 357 enrolled patients, 309 were evaluable; most patients received ixazomib alongside lenalidomide (98%) and dexamethasone (97%); 61% had received 2-3 prior lines of therapy. Median PFS was 15.6 months (95% confidence interval [CI]: 12.0-20.6) in all evaluable patients, and 19.6 (95% CI: 12.1-27.0) and 13.9 (95% CI: 10.1-18.1) months in patients who received 1 and ≥ 2 prior lines of therapy, respectively. The overall response rate was 67% in all evaluable patients, and 72% and 63%, respectively, in patients who received 1 and ≥ 2 prior lines of therapy. Median overall survival was 35.5 months. The ixazomib safety profile was consistent with previous reports. CONCLUSION: This study supports ixazomib-based therapy as an effective and tolerable treatment in the real-world. Outcomes were favorable in patients with 1 or ≥ 2 prior lines of therapy who were not lenalidomide- or PI-refractory.
650    _2
$a lidé $7 D006801
650    12
$a mnohočetný myelom $7 D009101
650    _2
$a lenalidomid $x terapeutické užití $7 D000077269
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a prospektivní studie $7 D011446
650    _2
$a dexamethason $x terapeutické užití $7 D003907
650    _2
$a lokální recidiva nádoru $x farmakoterapie $7 D009364
650    _2
$a protokoly antitumorózní kombinované chemoterapie $x škodlivé účinky $7 D000971
650    _2
$a uvea $7 D014602
650    12
$a sloučeniny boru $7 D001896
650    _2
$a glycin $x analogy a deriváty $7 D005998
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Ramasamy, Karthik $u Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
700    1_
$a Mateos, María-Victoria $u Department of Hematology, University Hospital of Salamanca, IBSAL, CIC, IBMCC (USAL-CSIC), Salamanca, Spain
700    1_
$a Kishore, Bhuvan $u Heart of England/University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
700    1_
$a Gergely, Varga $u Faculty of Medicine Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary
700    1_
$a Ladicka, Miriam $u National Cancer Institute, Bratislava, Slovakia
700    1_
$a Ori, Alessandra $u MediNeos, Observational Research, Modena, Italy
700    1_
$a Simoni, Lucia $u MediNeos, Observational Research, Modena, Italy
700    1_
$a Bent-Ennakhil, Nawal $u Takeda Pharmaceuticals International AG, Zurich, Switzerland
700    1_
$a Stull, Dawn Marie $u Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA
700    1_
$a Gavini, François $u Takeda Pharmaceuticals International AG, Zurich, Switzerland
700    1_
$a Terpos, Evangelos $u Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
700    1_
$a Hájek, Roman $u Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic; Department of Haematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
773    0_
$w MED00180199 $t Clinical lymphoma, myeloma & leukemia $x 2152-2669 $g Roč. 24, č. 2 (2024), s. e40-e49.e3
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37996265 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423155920 $b ABA008
999    __
$a ok $b bmc $g 2081394 $s 1217159
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 24 $c 2 $d e40-e49.e3 $e 20231014 $i 2152-2669 $m Clinical lymphoma, myeloma & leukemia $n Clin Lymphoma Myeloma Leuk $x MED00180199
LZP    __
$a Pubmed-20240412

Najít záznam

Citační ukazatele

Možnosti archivace